Page 13 - Aurobindo Pharma

Aurobindo's US manufacturing facility gets inspectional observations

The US drug regulator inspected the plant from January 13 to February 12,2020 and issued a letter to the company to this effect while classifying the inspection as 'Official Action Indicated'

Aurobindo Pharma gains 5%, hits 52-week high as Q4 net profit jumps 45% YoY

That apart, the company informed the exchanges that the US FDA has classified the inspection of the company's oral solids formulation manufacturing facility at New Jersey as Official Action Indicated

Aurobindo Pharma Q4 PBT rises 32% to Rs1077.51 cr over higher revenue

Revenues from operations for the quarter under review registered 16.4% growth at Rs 6158.43 crore as compared to Rs 5324.47 crore in the year ago period

Market Ahead, June 3: Top factors that could guide markets today

Tata Motors' stock could be active in today's session after the company announced that it has resumed operations across all its manufacturing plants in the country

Pharma, chemical stocks lead under lockdown, Aurobindo is top performer

Within BSE-500, 79% stocks gave positive returns in two months of lockdown

Covid-19 impact: Indian firms look to fill in for US' Famotidine crunch

Some see this as an opportunity for Indian firms like Alembic, Aurobindo who make both the bulk drug and the formulation

Aurobindo extends rally after US FDA clears Unit IV, zooms 133% in a month

The stock hit a 52-week low of Rs 281 on March 23, 2020

US FDA clears Aurobindo Pharma Unit IV, reverts classification to VAI

The latest classification, VAI, suggests that though certain objectionable conditions were found during the review, they did not warrant any further regulatory action

Aurobindo Pharma gains 15% as USFDA grants VAI to Unit IV facility

The facility remains important as it contributes more than 10 per cent to Aurobindo's overall sales and about 20 per cent of the US sales

Novartis scraps sale of assets including Covid-19 drug to Aurobindo Pharma

Novartis is donating 130 million hydroxychloroquine doses to support efforts against the epidemic, though the European Union has so far said there is no proof it works.

Aurobindo Pharma faces class action suit in US for concealing facts

Aurobindo Pharma allegedly concealed facts about cancer-causing agent NDMA in type-2 diabetes drug metformin

Aurobindo Pharma's debt pain recedes after calling off deal with Sandoz

Aurobindo was scheduled to acquire the portfolio with an upfront purchase price of $900 million in cash

Aurobindo Pharma gains 12% after USFDA issued EIR for Hyderabad facility

The stock is trading higher for the fourth straight day and has rallied 38 per cent during the period.

Aurobindo Pharma slips 17% as USFDA revokes VAI status for Unit-IV

Currently, Unit 4 has 15 abbreviated new drug applications (ANDA) approvals pending over the next one year.

US FDA revokes EIR issued to Aurobindo Pharma's Unit IV facility

On February 18, the US FDA issued the EIR with voluntary action indicated for Aurobindo Pharma's Unit IV injectable formulations unit

USFDA nod to Unit IV a breather for Aurobindo Pharma; share price up 20.4%

Analysts remain positive on Aurobindo's future prospects including the US despite the higher base

Aurobindo Pharma soars 19% as Unit IV receives EIR with VAI status from FDA

The Company has received the Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAl) status from the US Food & Drug Administration (USFDA) for Unit IV.

Aurobindo Pharma gains 5% post December quarter results

The stock of the drug company was trading higher for the fifth straight day, up 14 per cent, against a 4 per cent rise in the S&P BSE Sensex during the period.

Aurobindo Pharma Q3 net marginally down at Rs 705 cr, revenue up 12%

According to a filing with the bourses, revenues from operations during the quarter under review was up by nearly 12 per cent to Rs 5,895 crore. It was Rs 5,269.7 crore in Q3 FY19.

Aurobindo Pharma Q3 PBT rises 6% to Rs 942.8 cr; revenues up 11.9%

The formulations revenues for the quarter posted a growth of 17.4 per cent year-on-year at Rs 5,104 cr